Who Owns Celldex Therapeutics Stock?
NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 114.42%
- Institutions (% of float)
- 114.73%
- Held by insiders
- 0.27%
- Institutional holders
- 335
- Institutions 99.7%
- Insiders 0.3%
- Public and other 0.0%
Who owns Celldex Therapeutics stock?
Institutional investors own about 114.4% of Celldex Therapeutics's shares, spread across 335 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.27% of CLDX.
The largest institutional holders are Wellington Management Group, LLP (13.58%), FMR, LLC (10.99%) and Blackrock Inc. (8.84%). Together, the top 10 institutions control 62.9% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their CLDX positions and 5 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of CLDX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Wellington Management Group, LLP | 10.67M | 13.58% | +11.8% |
| FMR, LLC | 8.64M | 10.99% | +132.0% |
| Blackrock Inc. | 6.95M | 8.84% | -0.8% |
| Kynam Capital Management, LP | 5.07M | 6.45% | -4.8% |
| Price (T.Rowe) Associates Inc | 4.39M | 5.58% | -6.4% |
| State Street Corporation | 3.48M | 4.43% | -10.8% |
| Vanguard Capital Management LLC | 3.48M | 4.42% | +0.3% |
| Baker Bros. Advisors, LP | 2.56M | 3.26% | +116.9% |
| Deep Track Capital, Lp | 2.13M | 2.71% | -27.7% |
| Geode Capital Management, LLC | 2.05M | 2.61% | +1.3% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of CLDX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3.78M | 4.82% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.49M | 3.17% |
| iShares Trust-iShares Russell 2000 ETF | 2.02M | 2.57% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.60M | 2.04% |
| Vanguard Explorer Fund | 1.45M | 1.84% |
| T. Rowe Price New Horizons Fund, Inc. | 1.25M | 1.60% |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.04M | 1.32% |
| T. ROWE PRICE QUANTITATIVE Mgmt Fd.S, INC.-T. Rowe Price Integrated U. | 970.81K | 1.24% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 951.17K | 1.21% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 897.53K | 1.14% |
Frequently asked questions
Who is the largest shareholder of Celldex Therapeutics?
Wellington Management Group, LLP is the largest institutional shareholder of CLDX, owning 13.58% of shares outstanding (10.67M shares) as of its latest 13F filing.
What percentage of Celldex Therapeutics is owned by institutions?
Institutions own about 114.4% of CLDX shares and 114.7% of the public float.
How much of Celldex Therapeutics do insiders own?
Insiders, such as officers and directors, own about 0.27% of CLDX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.